University Of Melbourne

The University of Melbourne, located in Parkville, Victoria, Australia, is a prominent international research institution registered with the U.S. federal government to receive awards and registered in SAM.gov since May 5, 2007. As an international non-profit organization, the University of Melbourne provides advanced research and development services to federal agencies across multiple scientific and medical domains, including biomedical research, biotechnology, aerospace engineering, and technology development. The institution has established itself as a credible research partner for the U.S. government, leveraging its expertise in sophisticated scientific investigations to support national priorities in defense, health, and innovation.

While the University of Melbourne has not served as a prime federal contract awardee, it has received multiple federal contract sub-awards through partnerships with leading U.S. research institutions. The university has participated as a sub-contractor through prime contractors including Emory University, Boston University, and the University of Georgia Research Foundation. These sub-contract efforts have focused on specialized research activities, such as zinc ionophore development to combat antibiotic resistance in bacterial pathogens, influenza immunology studies including tetramer analysis of influenza-specific T cells, and centers of excellence for influenza disease research. The university's sub-contract work has been funded through various defense and health-related federal agencies, demonstrating its capacity to contribute to collaborative research initiatives with established U.S. research partners.

The University of Melbourne has been significantly more active as a prime recipient of federal grant awards, securing over 40 prime federal grant awards totaling tens of millions of dollars across multiple funding agencies and research domains. The institution's grant portfolio is dominated by biomedical and health-related research funded primarily through the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420), with major awards focused on cancer research including breast cancer senescent cell targeting ($4.3 million), ovarian cancer outcomes and acquired resistance ($1.07 million), and melanoma progression studies ($733,068). Additionally, the university has received significant funding from the National Institutes of Health for diabetes research, including a $987,196 award from the National Institute of Diabetes and Digestive and Kidney Diseases for ketone monitoring in type 1 diabetes, and HIV research funding of $394,820 from the National Institute of Allergy and Infectious Diseases for CRISPR-based therapeutic approaches. The university also holds grants from the Defense Advanced Research Projects Agency for the COASTERCHASE program ($821,000) and ENVISION program, as well as research awards from the Office of Naval Research, National Institute of Neurological Disorders and Stroke, and the Air Force Research Laboratory for projects ranging from fluid dynamics and aerodynamics to neuroscience and sensory network imaging. Beyond prime awards, the University of Melbourne participates extensively as a sub-grantee under leading U.S. institutions including Washington University (DIAN-TU Alzheimer's disease trials), Stanford University, New York University, Columbia University, Dana-Farber Cancer Institute, and Fred Hutchinson Cancer Center, contributing specialized laboratory work, data analysis, biospecimen management, and scientific oversight to collaborative multi-institutional research efforts in oncology, neurodegenerative diseases, malaria epidemiology, and immunology.